ClinicalTrials.gg
CompletedNCT03863899TF-TAVIUpdated Jan 18, 2020

Analgesia in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation (TF-TAVI)

An interventional study of Nerve block and Local infiltration in Aortic Valve Stenosis, sponsored by Medical University of Gdansk. Completed at 1 site in Poland. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-01-18.

Sponsored by Medical University of Gdansk · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Ilioinguinal and iliohypogastric (ILIH) nerve blocks are frequently performed for analgesia in inguinal surgery.

The investigators hypothesized that preoperative ultrasound-guided ilioinguinal and iliohypogastric (ILIH) nerve blocks will produce better intraoperative analgesia and less analgesic requirement postoperatively in comparison to commonly used preoperative local infiltration anaesthesia for patients undergoing transfemoral transcatheter aortic valve implantation (TF-TAVI).

Read the detailed description

It is a prospective, randomized trial.

The patients will be randomized to one of the 2 groups:

Group 1 - NERVE BLOCK. Ultrasound-guided ILIH nerve block will be performed by attending anaesthesiologist.

Group 2 - LOCAL INFILTRATION. Local anaesthetic infiltration of the operative area will be performed by operator.

During surgery patients will receive low-dose propofol infusion in order to achieve conscious sedation level, when indicated.

An extra dose of local anaesthetic drug for infiltration of the surgical field or intravenous fentanyl or/and intravenous paracetamol will be given as rescue analgesics in patients reporting pain sensation.

The patients will be observed for 24 hours. The pain at rest will be assessed using numeric rating scale (NRS 0 -10; 0 = no pain: 10 = max pain imaginable).

On the first postoperative day intravenous analgesics will be given on demand (paracetamol 1 g iv (if NRS \<5) and oxycodone 2,5 mg iv (if NRS > or = 5)).

02

Conditions studied

  • Aortic Valve Stenosis

Keywords

  • Ilioinguinal Iliohypogastric nerve block
  • local anaesthesia infiltration
  • ultrasound-guided
  • pain control
03

In context

Aortic Valve Stenosis

1,006 studies on the registry are indexed under Aortic Valve Stenosis; 284 are open to participants now.

This study's enrollment of 100 is below the median of 120 across 537 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Medical University of Gdansk is the lead sponsor of 133 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with aortic valve stenosis referred for TF-TAVI
  • using a minimalist approach of local anesthesia or nerve block with conscious sedation

Exclusion criteria

Exclusion Criteria:

  • patient's refusal to participate
  • allergy to local anaesthetic
  • TF-TAVI requiring general anesthesia or surgical cut-down
  • patients with major cognitive impairment and inability to assess their pain level in Numerical Rating Scale (NRS).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Nerve block

    ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)

    Procedure: Nerve block · Procedure: TAVI · Drug: Additional intraoperative analgesia · Drug: Additional postoperative analgesia

  • Active comparator
    Local infiltration

    local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)

    Procedure: Local infiltration · Procedure: TAVI · Drug: Additional intraoperative analgesia · Drug: Additional postoperative analgesia

Interventions

  • ProcedureNerve block

    drug mixture: 10-15 ml 0.5% ropivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline

    Also known as: Ultrasound-guided ilioinguinal iliohypogastric nerve block

  • ProcedureLocal infiltration

    15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)

    Also known as: Local anesthesia infiltration

  • ProcedureTAVI

    Insertion of an aortic valve prothesis through the aorta accessed through femoral artery

    Also known as: Transaortic valve implantation

  • DrugAdditional intraoperative analgesia

    Administration of any analgesics during the operation

    Also known as: AIA

  • DrugAdditional postoperative analgesia

    Administration of any analgesics within first 24 hours after the operation

    Also known as: APA

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS)

    The numeric rating scale will be used to determine the intraoperative and postoperative pain intensity levels of the patients. Pain intensity is scored 0-10 (0=no pain, 10=the worst pain imaginable). The pain intensity will be measured at 5 time points intraoperatively (femoral artery cannulation, aortic valve system introduction, aortic valve system removal, vessel closure devices insertion and the end of the operation) and at 2 time intervals postoperatively (0-12 hours and 12-24 hours).

    Time frame: 24 hours

Secondary outcomes

  1. Additional intraoperative analgesia consumption

    Fentanyl and paracetamol consumption during the operation.

    Time frame: 24 hours

  2. Additional postoperative analgesia consumption

    Oxycodone and paracetamol consumption in first 24 hours after the operation

    Time frame: 24 hours

  3. Patient satisfaction with analgesia

    Categorical quantification: Yes / No

    Time frame: 3 days

  4. Intraoperative and postoperative cost calculations

    Sum of anesthetics and analgesics administered during operation and within first 24 hours after operation

    Time frame: 1 year

07

Study locations

1 site
  • University Clinical Centre
    Gdansk, 80-211, Poland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2019, 17 months.

Of 174 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 17 months is below that.

Counting every sponsor, half of 277 studies reached it within 33 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2018
First posted
Mar 5, 2019
StartActual
Jul 2, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Last update
Jan 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03863899
Responsible party
Liudmila Hasak, MD, PhD (Principal Investigator, Medical University of Gdansk) — Principal investigator
First posted
Mar 5, 2019
Start date
Jul 2, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Jan 18, 2020

Study contacts

Romuald Lango, MD, PhD
study chair · Department of Cardiac Anaesthesiolgy UCC of Gdansk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion